Trelagliptin Succinate, also known as the succinate salt of Trelagliptin, is a novel ultra-long-acting oral hypoglycemic drug belonging to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors.
Basic Information
English Name: Trelagliptin Succinate
CAS Number: 1029877-94-8
Molecular Formula: C22H26FN5O6
Molecular Weight: 475.48
Pharmacological Action
Trelagliptin Succinate works by inhibiting the activity of dipeptidyl peptidase 4 (DPP-4), which decreases the degradation of glucagon-like peptide-1 (GLP-1). This, in turn, promotes insulin secretion and exerts a hypoglycemic effect. DPP-4 is an enzyme that inactivates incretin hormones such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), both of which play crucial roles in blood glucose regulation. By inhibiting DPP-4, Trelagliptin Succinate enhances glucose-dependent insulin secretion, thereby controlling blood glucose levels.
Clinical Applications
Indications: Primarily used for the treatment of type 2 diabetes mellitus (T2DM).
